Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 1,999 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Follow-Up Questions
What is the price performance of GH stock?
The current price of GH is $90.9, it has decreased 7.36% in the last trading day.
What are the primary business themes or industries for Guardant Health Inc?
Guardant Health Inc belongs to Health Care industry and the sector is Health Care
What is Guardant Health Inc market cap?
Guardant Health Inc's current market cap is $11.3B
Is Guardant Health Inc a buy, sell, or hold?
According to wall street analysts, 27 analysts have made analyst ratings for Guardant Health Inc, including 13 strong buy, 16 buy, 3 hold, 1 sell, and 13 strong sell
